Medication choices in neurocritical care are inseparable from physiology: stop seizures without causing secondary hypotension, reduce intracranial pressure while preserving perfusion, and choose titratable blood-pressure therapy without overshoot.
Compare levetiracetam, fosphenytoin and IV valproate after benzodiazepine-treated status epilepticus.
Use continuous anesthetic therapy for refractory status with EEG rather than treating visible movement alone.
Choose hypertonic saline versus mannitol from sodium, volume status, renal function and hemodynamics.
Use nicardipine, clevidipine or labetalol as titratable BP tools according to the neuro syndrome and patient physiology.
Recognize magnesium sulfate as disease-specific seizure prevention/treatment in eclampsia rather than a generic antiseizure substitute.
The table below is a selection framework. Open the individual monograph for exact dosing, preparation, renal/CRRT/IHD adjustment, interactions and evidence traceability.
ICU role: Common second-line antiseizure drug after benzodiazepines in established status epilepticus.
Monitor: Renal function, sedation/behavior, seizure/EEG response.
ICU role: Parenteral prodrug of phenytoin for established status and selected seizure indications.
Monitor: ECG/BP during load, albumin/free phenytoin when relevant, interactions.
ICU role: Broad-spectrum IV antiseizure therapy and established-status option.
Monitor: LFTs, platelets, ammonia when encephalopathy suspected, level when useful.
ICU role: Rapidly titratable anesthetic for refractory status and neuro-ICU sedation.
Monitor: BP, EEG target, triglycerides/CK/lactate with prolonged high dose.
ICU role: Continuous benzodiazepine anesthetic for refractory status and selected deep sedation.
Monitor: EEG, BP, wake-up delay, renal/hepatic function.
ICU role: NMDA antagonist used as adjunct in refractory/super-refractory status and selected neuro-ICU analgosedation.
Monitor: EEG, BP/HR, sedation/secretions.
ICU role: Hyperosmolar therapy for cerebral edema/herniation and symptomatic hyponatremia—two different indications with different endpoints.
Monitor: Sodium/chloride/osmolality, renal function, neurologic/ICP response.
ICU role: Osmotic diuretic for acute intracranial hypertension/herniation.
Monitor: Hemodynamics, renal function, osmolality/osmolar gap per local protocol.
ICU role: Titrated arterial vasodilator widely used for acute neurocritical BP control.
Monitor: Continuous BP, neurologic exam, infusion-site considerations.
ICU role: Ultra-short-acting dihydropyridine infusion for precise BP control.
Monitor: Continuous BP, triglyceride/lipid load in prolonged use.
ICU role: IV alpha/beta blocker for bolus or infusion BP control in selected neuro emergencies.
Monitor: BP, HR, bronchospasm/AV conduction.
ICU role: First-line anticonvulsant for eclampsia prevention/treatment, not a general substitute for standard status agents.
Monitor: Reflexes, respiratory rate, urine output/renal function; serum level when indicated.
| Agent | ICU role | Why I choose it | Why I hesitate | What I monitor |
|---|---|---|---|---|
| Levetiracetam Second-Generation Antiepileptic / SV2A Ligand | Common second-line antiseizure drug after benzodiazepines in established status epilepticus. | ✓ Minimal hemodynamic effects and fewer drug interactions make it attractive in many ICU patients. | ✕ Renal clearance requires adjustment; efficacy is not universally superior to fosphenytoin/valproate. | Renal function, sedation/behavior, seizure/EEG response. |
| Fosphenytoin Water-Soluble Phenytoin Prodrug / Voltage-Gated Sodium Channel Blocker | Parenteral prodrug of phenytoin for established status and selected seizure indications. | ✓ Effective second-line option when sodium-channel blockade fits the patient. | ✕ Hypotension/arrhythmia during loading; interactions and protein-binding issues complicate interpretation. | ECG/BP during load, albumin/free phenytoin when relevant, interactions. |
| Valproate (IV) Broad-Spectrum Antiepileptic / GABA Transaminase Inhibitor | Broad-spectrum IV antiseizure therapy and established-status option. | ✓ Useful when hemodynamic tolerance is important and liver/pregnancy constraints are absent. | ✕ Hepatic failure, hyperammonemia, thrombocytopenia and teratogenicity. | LFTs, platelets, ammonia when encephalopathy suspected, level when useful. |
| Propofol Intravenous Sedative-Hypnotic Agent | Rapidly titratable anesthetic for refractory status and neuro-ICU sedation. | ✓ Fast onset/offset permits EEG seizure suppression and serial neurologic reassessment when hemodynamics permit. | ✕ Hypotension, triglycerides and PRIS with escalating/prolonged high-dose exposure. | BP, EEG target, triglycerides/CK/lactate with prolonged high dose. |
| Midazolam Short-Acting Benzodiazepine | Continuous benzodiazepine anesthetic for refractory status and selected deep sedation. | ✓ Familiar, effective antiseizure infusion when rapid continuous therapy is needed. | ✕ Accumulation, hypotension and delayed awakening, especially with renal/hepatic dysfunction. | EEG, BP, wake-up delay, renal/hepatic function. |
| Ketamine Dissociative NMDA Receptor Antagonist | NMDA antagonist used as adjunct in refractory/super-refractory status and selected neuro-ICU analgosedation. | ✓ Mechanistically useful when GABAergic therapy is failing and hypotension limits deeper propofol/midazolam. | ✕ Not hemodynamically neutral in catecholamine depletion; secretion/emergence effects and evidence context matter. | EEG, BP/HR, sedation/secretions. |
| Hypertonic Saline (3%) Hyperosmolar Agent / Concentrated Electrolyte Solution | Hyperosmolar therapy for cerebral edema/herniation and symptomatic hyponatremia—two different indications with different endpoints. | ✓ Useful when volume expansion is acceptable and sodium can be closely monitored. | ✕ Hypernatremia, chloride load and overly rapid sodium correction when used for hyponatremia. | Sodium/chloride/osmolality, renal function, neurologic/ICP response. |
| Mannitol Osmotic Diuretic / Hyperosmolar Agent | Osmotic diuretic for acute intracranial hypertension/herniation. | ✓ Useful when hyperosmolar therapy is needed and blood pressure/renal function can tolerate osmotic diuresis. | ✕ Hypotension, AKI and accumulation in renal failure. | Hemodynamics, renal function, osmolality/osmolar gap per local protocol. |
| Nicardipine Dihydropyridine Calcium Channel Blocker | Titrated arterial vasodilator widely used for acute neurocritical BP control. | ✓ Smooth continuous BP control in ICH/ischemic stroke contexts when a titratable infusion is desired. | ✕ Hypotension/overshoot and reflex tachycardia; target is syndrome-specific. | Continuous BP, neurologic exam, infusion-site considerations. |
| Clevidipine Ultra-Short-Acting Dihydropyridine Calcium Channel Blocker | Ultra-short-acting dihydropyridine infusion for precise BP control. | ✓ Useful when rapid titration and short offset are priorities. | ✕ Lipid emulsion considerations and cost/formulary access; hypotension remains possible. | Continuous BP, triglyceride/lipid load in prolonged use. |
| Labetalol Combined Alpha-1 and Non-Selective Beta Blocker | IV alpha/beta blocker for bolus or infusion BP control in selected neuro emergencies. | ✓ Useful when tachycardia accompanies hypertension and bronchospasm/bradycardia are absent. | ✕ Bradycardia, heart block, bronchospasm, acute decompensated pump failure. | BP, HR, bronchospasm/AV conduction. |
| Magnesium Sulfate Electrolyte / Multi-Mechanism Membrane & Neuromuscular Modulator | First-line anticonvulsant for eclampsia prevention/treatment, not a general substitute for standard status agents. | ✓ Disease-specific therapy in preeclampsia/eclampsia. | ✕ Renal failure increases toxicity risk; loss of reflexes/respiratory depression occur with accumulation. | Reflexes, respiratory rate, urine output/renal function; serum level when indicated. |
Why: Comparative evidence shows broadly similar second-line success; hemodynamics, liver disease, pregnancy, interactions and renal function matter.
Why: Once paralyzed/sedated, clinical examination cannot reliably show seizure control.
Why: ICP therapy cannot sacrifice systemic perfusion.
Why: Smooth control and avoidance of variability/overshoot are central.
Why: Eclampsia has a disease-specific therapy and obstetric definitive management.
Recognition becomes selection, then organ-failure adjustment, competing physiology and senior-level prioritization.
Convulsive status persists after adequate benzodiazepine. BP is stable, liver and kidney function are normal.
Levetiracetam, fosphenytoin or IV valproate are all reasonable second-line choices. Use the local protocol and patient-specific contraindications rather than claiming one universally wins.
A cirrhotic patient remains in status after benzodiazepine. Platelets are low and transaminases are markedly elevated.
Valproate becomes less attractive; levetiracetam may offer a simpler interaction/hepatic profile, while fosphenytoin still requires hemodynamic and protein-binding awareness.
A TBI patient acutely herniates with MAP 55 mmHg and oliguria.
Give immediate hyperosmolar rescue while correcting hypotension. Hypertonic saline may be favored over mannitol when further osmotic diuresis/hypotension is undesirable. Protect CPP and move to definitive neurosurgical management.
A patient with ARDS is paralyzed for ventilation and develops persistent electrographic seizures after second-line antiseizure therapy.
Treat electrographic status with an anesthetic infusion and continuous EEG. TOF/absence of movement cannot be used as the seizure endpoint because paralysis masks motor activity.
Large ICH, SBP 225, rising ICP and marginal CPP. The team wants an immediate large labetalol bolus to normalize BP.
Use controlled titratable BP reduction while simultaneously addressing ICP and monitoring CPP/neurologic trajectory. The objective is not normal blood pressure at any cost; avoid abrupt overshoot that worsens cerebral perfusion.
Workhorse broad-spectrum IV antiepileptic targeting synaptic vesicle protein SV2A, used off-label as one of the established second-line options for benzodiazepine-refractory convulsive status epilepticus (ESETT: 60 mg/kg, max 450…
Water-soluble phosphate ester prodrug of phenytoin dosed in Phenytoin Equivalents (PE), providing rapid IV/IM delivery without propylene glycol-induced cardiac toxicity or purple glove syndrome for status epilepticus.
Potent broad-spectrum parenteral antiepileptic that enhances brain GABA levels and blocks voltage-dependent sodium and T-type calcium channels, used off-label as one of the established second-line options for benzodiazepine-refra…
Rapid-onset, short-acting IV sedative-hypnotic for mechanical ventilation sedation and ICP control — lowers cerebral metabolic demand ($CMRO_2$) but risks severe hypotension and Propofol Infusion Syndrome (PRIS).
Short-acting benzodiazepine used for procedural/anesthetic sedation, ICU sedation and seizure management. With continuous or repeated dosing, recovery can be prolonged, especially in renal dysfunction, hepatic disease, older age …
Dissociative NMDA antagonist providing analgesia, sedation, and bronchodilatory effects; often useful for RSI or selected ICU analgo-sedation scenarios, but not universally superior to other induction/sedation agents.
High-tonicity sodium solution (513 mEq/L Na⁺ and Cl⁻, 1026 mOsm/L) used for rapid osmotic intracranial pressure reduction in cerebral herniation and for emergent correction of severe symptomatic hyponatremia.
Non-reabsorbable six-carbon sugar alcohol (20% solution = 1098 mOsm/L) that establishes an osmotic gradient across the blood-brain barrier to reduce brain volume and ICP, followed by profound renal osmotic diuresis.
Potent intravenous arterial vasodilator for acute hypertensive emergencies, intracerebral hemorrhage (ICH), and stroke — highly selective arterial vasodilation with minimal venodilation or cardiodepression.
Ultra-short-acting IV arterial vasodilator cleared by blood esterases (half-life 1 min) for precise titratable blood pressure control in acute hypertensive emergencies.
Combined alpha-1 and beta-1/beta-2 blocker (1:7 alpha:beta ratio IV) for hypertensive emergencies, stroke, and aortic dissection — lowers BP and HR simultaneously.
Spans four genuinely distinct ICU indications — torsades de pointes, adjunctive severe asthma therapy, eclampsia/severe preeclampsia, and simple hypomagnesemia repletion — each with its own mechanism-relevant dosing; no single do…
This Masterclass teaches selection and reasoning. Exact dosing, concentration, infusion preparation, renal/hepatic/RRT adjustment and monitoring must be checked in the linked medication monograph and the institution's current formulary/protocol. Local resistance patterns and regulatory drug availability can change faster than a static teaching page.